CDEK
← All drugs Report issue

polidocanol

Trade name: asclera

Small moleculeapproved

Approved

Mar 30, 2010

Dodecyl Ethyleneglycol Monoether (lauryl ethoxylate) is a nonionic compound, that used as environmentally friendly non-Ionic surfactant with marked antibacterial activity. Dodecyl Ethyleneglycol Monoether is effective permeation enhancer, both for the passive process as well as for samples subjected to iontophoresis. — NCATS

Clinical trial activity

40 trials · 47 clinical orgs · 2 marketing orgs

Phase 1
5
Phase 2
15
Phase 3
6
Phase 4
10

Earliest trial started Mar 1, 2004 (NCT00348764)

Timeline

2000s

  1. Jan 1, 2004

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2006

    Earliest Phase 1 Sponsor(trial)

  3. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Mar 30, 2010

    Chemische Fabrik Kreussler & CO GmbH — Earliest FDA Approval

  2. Mar 30, 2010

    Chemische Fabrik Kreussler & CO GmbH — NDA Organization

  3. Mar 30, 2010

    Chemische Fabrik Kreussler & CO GmbH — NDA Secondary Org

  4. Nov 25, 2013

    BTG — NDA Secondary Org

Indications

Approved for

Studied for

Mechanism of action

  • Unspecified targetOTHER

    Unknown

Approval history

  • approvedMar 30, 2010

Chemistry & pharmacology

Loading structure…

SMILES

CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO
Mol. weight
582.82 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Availability
Prescription Only

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • aethoxysclerol
  • aethoxysclerol
  • aethoxysclerol
  • aethoxysklerol
  • aethoxysklerol
  • aethoxysklerol
  • aethoxysklerol
  • aethoxy-sklerol
  • aethoxy-sklerol
  • aetoxisclerol
  • alpha-dodecyl-omega-hydroxypoly(oxy-1,2ethanediyl)
  • asclera
  • asclera
  • asclera
  • atossisclerol
  • atoxysclerol
  • ethoxysclerol
  • hydroxypolyethoxydodecane
  • laureth
  • laureth-4
  • laureth-7
  • laureth 9
  • laureth 9
  • laureth 9
  • laureth 9
  • laureth-9
  • laureth-9
  • laureth-9
  • laureth-9
  • lauromacrogol
  • lauromacrogol
  • lauromacrogol
  • lauromacrogol 400
  • lauromacrogol 400
  • lauromacrogol 400
  • lubrol 12a9
  • lubrol-px
  • macrogol 9 lauryl ether
  • macrogol 9 lauryl ether
  • nonaethylene glycol monododecyl ether
  • nonaethylene glycol monododecyl ether
  • nonaethylene glycol monododecyl ether
  • nonaethyleneglycol monododecyl ether
  • nonaethylene glycol monolauryl ether
  • nonaethylene glycol monolauryl ether
  • peg-9 lauryl ether
  • peg-9 lauryl ether
  • polidocanol
  • polidocanol
  • polidocanol
  • polidocanol
  • polidocanol
  • polidocanol
  • polidocanol
  • polidocanol
  • polidocanol
  • polidocanol
  • polydocanol
  • polydocanol
  • polyethylene glycol 450 lauryl ether
  • polyethylene glycol 450 lauryl ether
  • polyethylene glycol monododecyl ether
  • polyoxyethylene-4-dodecyl ether
  • polyoxyethylene 9-lauryl ether
  • polyoxyethylenedodecyl ether
  • polyoxyethylene lauryl ether
  • polyoxyl 9 lauryl ether
  • polyoxyl 9 lauryl ether
  • tetraethyleneglycol lauryl ether
  • thesit
  • varithena

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07276243N/AJan 1, 2026Rio de Janeiro State University
NCT06749665N/ADec 20, 2024Sohag University
NCT07307131Phase 2Sep 1, 2024Benha University
NCT06300502Phase 1Jun 30, 2024Harvard University, Johns Hopkins University
NCT06132165Phase 1Dec 1, 2023Harvard University, Johns Hopkins University
NCT05760248Phase 2May 4, 202310xBio, LLC, Therapeutics, Inc.
NCT05798936Phase 4Apr 1, 2023Assiut University
NCT05312970Phase 4Dec 31, 2022Boston Scientific Corporation
NCT06120036Phase 1Dec 6, 2022Harvard University, Johns Hopkins University
NCT05154955Phase 2Oct 19, 202110xBio, LLC
NCT04398823Phase 4May 15, 2020Anhui Medical University, BaoShan People's Hospital, Changzhi City People's Hospital, Ganzhou City People's Hospital, Jiao Tong University, Luoyang Central Hospital, People's Liberation Army of China, Shandong Maternal and Chidl Care Service Center, Shanghai Construction Group Hospital, Sichuan University, Zhengzhou University
NCT04258761Phase 2Oct 10, 201910xBio, LLC
NCT04675177Phase 2/Phase 3 (Phase 3)Sep 1, 2019Centro Hospitalar do Porto, University of Porto
NCT03754140Phase 2May 31, 2019Melanoma Institute Australia, University of Sydney
NCT03791775Phase 2Dec 1, 2018Societa Italiana di Chirurgia ColoRettale, University of Catanzaro
NCT04091763Phase 2Aug 1, 2018University of Porto
NCT02988063Phase 4Apr 10, 2017BTG, OhioHealth
NCT02557542N/AOct 1, 2015University of London
NCT05468450N/AJul 1, 2015Societe Francaise de Phlebologie, Société Française de Phlébologie
NCT02468206N/AJun 1, 2015Sichuan University
Showing 20 of 40 trials
Page 1 / 2

Organizations

Research & Development (47)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
BTGFor profit9842007
Sichuan UniversityAcademic/Hospital4322015
10xBio, LLCFor profit3312019
Harvard UniversityAcademic/Hospital3312022
Johns Hopkins UniversityAcademic/Hospital3012022
Fundação de Amparo à Pesquisa do Estado de São PauloAcademic/Hospital2012012
Sao Paulo State UniversityAcademic/Hospital2212012
University of PortoAcademic/Hospital2222018
Aarhus UniversityAcademic/Hospital1012008
Anhui Medical UniversityAcademic/Hospital1012020
Assiut UniversityAcademic/Hospital1112023
BaoShan People's HospitalAcademic/Hospital1012020
Benha UniversityAcademic/Hospital1112024
Boston Scientific CorporationFor profit1112022
Centro Hospitalar do PortoAcademic/Hospital1012019
Changzhi City People's HospitalAcademic/Hospital1012020
China Medical UniversityAcademic/Hospital1112011
Foundation for Skin ResearchAcademic/Hospital1012014
Fudan UniversityAcademic/Hospital1112013
Ganzhou City People's HospitalAcademic/Hospital1012020
47 organizations
Page 1 / 3

Marketing (3)

OrganizationOrg typeRelationshipDate
BTGFor profitNDA2Nov 25, 2013
Chemische Fabrik Kreussler & CO GmbHFor profitNDAMar 30, 2010
Chemische Fabrik Kreussler & CO GmbHFor profitNDA2Mar 30, 2010